Mata-Castro Nieves, García-Chilleron Raimon, Gavilanes-Plasencia Javier, Ramírez-Camacho Rafael, García-Fernández Alfredo, García-Berrocal José Ramón
Servicio de Otorrinolaringología, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, España.
Servicio de Otorrinolaringología, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, España.
Acta Otorrinolaringol Esp (Engl Ed). 2018 Jul-Aug;69(4):214-218. doi: 10.1016/j.otorri.2017.08.004. Epub 2017 Oct 13.
To describe the results in terms of audiometric relapse-free survival and relapse rate in immunomediated hearing loss patients treated exclusively with corticosteroids.
Retrospective study of patients with audiometric relapses, monitored from 1995 to 2014, in two centres of the Community of Madrid.
We evaluated 31 patients with a mean age of 48.52 years (14.67 SD), of which 61.3% were women. Most hearing loss was fluctuating (48.4%). Only 16.1% of patients had systemic autoimmune disease. There is a moderate positive correlation between the sex variable and the systemic involvement variable (Spearman's correlation coefficient=0.356): specifically, between being female and systemic disease. The relative incidence rate of relapse in the first year was 2.01 relapses/year with a 95% CI (1.32 to 2.92). The mean survival time of the event (audiometric relapse) was 5.25 months (SD 0.756). With multivariate analysis, the only variable that achieved statistical significance was age, with a hazard ratio of 1.032 (95% CI; 1.001-1.063, P=.043).
Immune-mediated disease of the inner ear is a chronic disease with relapses. Half of the patients with immunomediated hearing loss treated exclusively with corticosteroids relapse before 6 months of follow-up. In addition, if a patient has not relapsed, they are more likely to relapse as each year passes. Analysis of the of audiometric relapse- free survival will enable the effect of future treatments to be compared and their capacity to reduce the rhythm of relapses.
描述仅接受皮质类固醇治疗的免疫介导性听力损失患者的听力复发-free生存率和复发率结果。
对1995年至2014年在马德里自治区两个中心监测的听力复发患者进行回顾性研究。
我们评估了31例平均年龄为48.52岁（标准差14.67）的患者，其中61.3%为女性。大多数听力损失为波动性（48.4%）。只有16.1%的患者患有全身性自身免疫性疾病。性别变量与全身受累变量之间存在中度正相关（Spearman相关系数=0.356）：具体而言，女性与全身性疾病之间。第一年的相对复发率为每年2.01次复发，95%置信区间为（1.32至2.92）。事件（听力复发）的平均生存时间为5.25个月（标准差0.756）。通过多变量分析，唯一达到统计学显著性的变量是年龄，风险比为1.032（95%置信区间；1.001-1.063，P=0.043）。
内耳免疫介导性疾病是一种有复发的慢性疾病。仅接受皮质类固醇治疗的免疫介导性听力损失患者中有一半在随访6个月前复发。此外，如果患者未复发，随着时间推移，他们复发的可能性更大。对听力复发-free生存率的分析将能够比较未来治疗的效果及其降低复发率的能力。
